Literature DB >> 27126661

Assessment of pathological response to neoadjuvant chemotherapy in locally advanced breast cancer using the Miller-Payne system and TUNEL.

C Shintia1, H Endang, K Diani.   

Abstract

BACKGROUND: Responses to neoadjuvant (before surgery) chemotherapy in locally advanced breast cancer (LABC) consist of clinical and pathological responses. Evaluating chemotherapy response is essential to predict survival rate and guide future chemotherapy. Until now, the evaluation of pathological response mainly involves quantitative assessment and is often inconsistent with clinical response. We explored the evaluation of pathological responses by both quantitative and qualitative methods, i.e. by evaluating the cellularity of tumour cells and the percentage of apoptosis. MATERIALS AND
METHOD: A cross-sectional analytical retrospective study was conducted on tissue of LABC diagnosed between 2010 and 2014 at the Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia Cipto Mangunkusumo Hospital and Division of Surgical Oncology, Cipto Mangunkusumo Hospital. Biopsy and resection specimens were compared to evaluate reduction in cellularity, which were subsequently categorized into stages of Miller-Payne (MP) classification. The resection specimens were stained with TUNEL and the percentage of apoptosis was calculated. Reduction in cellularity between biopsy and mastectomy specimens with TUNEL staining is evaluated as a modification of the MP method.
RESULTS: We found no association between clinical responses with percentage of apoptosis, MP pathological responses and modified MP. There was a correlation between the dead cell evaluated by MP and by modified MP (p=0.000).
CONCLUSION: Modified MP increases the degree or grading of pathological responses, but it does not improve the correlation with clinical response.

Entities:  

Mesh:

Year:  2016        PMID: 27126661

Source DB:  PubMed          Journal:  Malays J Pathol        ISSN: 0126-8635            Impact factor:   0.656


  5 in total

1.  Efficacy analysis of trastuzumab, carboplatin and docetaxel in HER-2-positive breast cancer patients.

Authors:  Di Wu; Liangfa Xiong
Journal:  Oncol Lett       Date:  2020-01-24       Impact factor: 2.967

2.  Association between the methylation status of PCDH17 and the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer.

Authors:  De-Di Kong; Rong-Zhan Fu; Liang Li; Wei Wang; Shi-Bing Wang
Journal:  Oncol Lett       Date:  2020-06-16       Impact factor: 2.967

3.  Discussion of relationships among changes of pathological indicators, postoperative lymphedema of the upper limb, and prognosis of patients with breast cancer.

Authors:  Xiping Zhang; Binbin Tang; Dehong Zou; Hongjian Yang; Enqi Qiao; Xiangming He; Feijiang Yu
Journal:  Biosci Rep       Date:  2019-04-16       Impact factor: 3.840

4.  Feasibility of quantitative and volumetric enhancement measurement to assess tumor response in patients with breast cancer after early neoadjuvant chemotherapy.

Authors:  Jie Ding; Hongyan Xiao; Weiwei Deng; Fengjiao Liu; Rongrong Zhu; Ruoshui Ha
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

5.  The Role of Intraperitoneal Intraoperative Chemotherapy with Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis from Ovarian Cancer-Hyperthermia versus Normothermia: A Randomized Controlled Trial.

Authors:  Angela Casado-Adam; Lidia Rodriguez-Ortiz; Sebastian Rufian-Peña; Cristobal Muñoz-Casares; Teresa Caro-Cuenca; Rosa Ortega-Salas; Maria Auxiliadora Fernandez-Peralbo; Maria Dolores Luque-de-Castro; Juan M Sanchez-Hidalgo; Cesar Hervas-Martinez; Antonio Romero-Ruiz; Javier Briceño; Álvaro Arjona-Sánchez
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.